BRPI0907237A2 - Anticorpo anti-cldn6 - Google Patents

Anticorpo anti-cldn6

Info

Publication number: BRPI0907237A2
Authority: BR; Brazil
Prior art keywords: cldn6 antibody; cldn6; antibody
Prior art date: 2008-01-11

Application number

BRPI0907237-3A

Other languages

English (en)

Inventor

Hiroyuki Aburatani

Shuichi Tsutsumi

Kunihiro Nishimura

Hirofumi Sakumoto

Shigeto Kawai

Original Assignee

Univ Tokyo

Forerunner Pharma Res Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-01-11

Filing date

2009-01-09

Publication date

2015-07-14

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40853092&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0907237(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-01-09 Application filed by Univ Tokyo, Forerunner Pharma Res Co Ltd filed Critical Univ Tokyo

2015-07-14 Publication of BRPI0907237A2 publication Critical patent/BRPI0907237A2/pt

Classifications

- G01N33/5758—
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- G01N33/5759—
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Engineering & Computer Science (AREA)
Cell Biology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Oncology (AREA)
Food Science & Technology (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Hospice & Palliative Care (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

BRPI0907237-3A 2008-01-11 2009-01-09 Anticorpo anti-cldn6 BRPI0907237A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2008004423		2008-01-11
PCT/JP2009/000082 WO2009087978A1 (ja)	2008-01-11	2009-01-09	抗cldn6抗体

Publications (1)

Publication Number	Publication Date
BRPI0907237A2 true BRPI0907237A2 (pt)	2015-07-14

Family

ID=40853092

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0907237-3A BRPI0907237A2 (pt)	2008-01-11	2009-01-09	Anticorpo anti-cldn6

Country Status (12)

Country	Link
US (1)	US9274119B2 (pt)
EP (3)	EP4282428A3 (pt)
JP (1)	JP5848863B2 (pt)
KR (1)	KR20100116179A (pt)
CN (1)	CN101918450A (pt)
AU (1)	AU2009203464A1 (pt)
BR (1)	BRPI0907237A2 (pt)
CA (1)	CA2711557A1 (pt)
MX (1)	MX2010007500A (pt)
RU (1)	RU2010133547A (pt)
SG (1)	SG187457A1 (pt)
WO (1)	WO2009087978A1 (pt)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2398902B1 (en)	2009-02-20	2023-10-04	Astellas Pharma Inc.	Methods and compositions for diagnosis and treatment of cancer
EP2494362B1 (en)	2009-10-26	2016-06-08	Externautics S.p.A.	Prostate tumor markers and methods of use thereof
WO2011051280A1 (en) *	2009-10-26	2011-05-05	Externautics S.P.A.	Ovary tumor markers and methods of use thereof
EP2322555A1 (en)	2009-11-11	2011-05-18	Ganymed Pharmaceuticals AG	Antibodies specific for claudin 6 (CLDN6)
SG10201500975YA (en) *	2009-11-11	2015-04-29	Ganymed Pharmaceuticals Ag	Antibodies specific for claudin 6 (cldn6)
CA3014767C (en)	2010-02-24	2023-08-29	Immunogen, Inc.	Folate receptor 1 antibodies and immunoconjugates and uses thereof
JP6158511B2 (ja) *	2010-06-11	2017-07-05	協和発酵キリン株式会社	抗ｔｉｍ−３抗体
EP2404936A1 (en)	2010-07-06	2012-01-11	Ganymed Pharmaceuticals AG	Cancer therapy using CLDN6 target-directed antibodies in vivo
MX349057B (es)	2010-11-30	2017-07-07	Chugai Pharmaceutical Co Ltd	Agente terapeutico que induce citotoxicidad.
MX346555B (es)	2011-04-01	2017-03-24	Immunogen Inc	Metodos para aumentar la eficacia de la terapia contra el cancer con receptor 1 de folato (folr1).
PT3026064T (pt) *	2011-05-13	2018-12-17	Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh	Anticorpos para tratamento de cancro que expressa claudina 6
RS54627B1 (sr) *	2011-05-13	2016-08-31	Ganymed Pharmaceuticals Ag	Antitela za terapiju kancera koji eksprimira klaudin 6
JP6281163B2 (ja)	2011-08-22	2018-02-21	エメルゲントバイオソリューションズカナダ	クロストリジウム・ディフィシレ抗体
EP2814509B1 (en) *	2012-02-17	2018-05-16	Seattle Genetics, Inc.	Antibodies to integrin v 6 and use of same to treat cancer
WO2013143555A1 (en) *	2012-03-26	2013-10-03	Biontech Ag	Rna formulation for immunotherapy
SG11201500938XA (en)	2012-08-31	2015-04-29	Immunogen Inc	Diagnostic assays and kits for detection of folate receptor 1
JP2014193853A (ja) *	2013-03-01	2014-10-09	Japan Health Sciences Foundation	抗体、フラグメント、医薬組成物、分子及び腫瘍マーカー
WO2015014376A1 (en)	2013-07-31	2015-02-05	Biontech Ag	Diagnosis and therapy of cancer involving cancer stem cells
MX371496B (es)	2013-08-30	2020-01-31	Immunogen Inc	Anticuerpos y ensayos para la detección del receptor 1 de folato.
JP6515111B2 (ja) *	2013-11-06	2019-05-22	アッヴィ・ステムセントルクス・エル・エル・シー	新規の抗クローディン抗体および使用方法
KR102551410B1 (ko)	2013-11-11	2023-07-04	추가이 세이야쿠 가부시키가이샤	개변된 항체 가변영역을 포함하는 항원 결합 분자
EP3126381B2 (en) *	2014-04-01	2022-02-16	Biontech Cell&Gene Therapies GmbH	Claudin-6-specific immunoreceptors and t cell epitopes
MA40921A (fr) *	2014-11-05	2017-09-12	Abbvie Stemcentrx Llc	Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation
TWI880146B (zh)	2014-11-11	2025-04-11	日商中外製藥股份有限公司	包含經改變之抗體可變區之抗原結合分子的資料庫
CN106146666B (zh) *	2015-03-26	2019-09-06	科济生物医药（上海）有限公司	靶向cldn6的免疫效应细胞及其制备方法和应用
CN108601828B (zh)	2015-09-17	2023-04-28	伊缪诺金公司	包含抗folr1免疫缀合物的治疗组合
WO2018005697A1 (en) *	2016-06-29	2018-01-04	The Regents Of The University Of California	Antibodies specific to sonic hedgehog and method of use thereof
CN110267984A (zh) *	2016-12-28	2019-09-20	国立大学法人大阪大学	抗紧密连接蛋白-2单克隆抗体
WO2019048040A1 (en)	2017-09-06	2019-03-14	Ganymed Pharmaceuticals Gmbh	ANTIBODIES USEFUL IN THE DIAGNOSIS OF CANCER
KR20250050137A (ko) *	2017-09-18	2025-04-14	더 리전트 오브 더 유니버시티 오브 캘리포니아	클라우딘6 항체 및 암치료방법
TWI885539B (zh)	2017-09-29	2025-06-01	日商第一三共股份有限公司	抗體－吡咯并苯二氮呯衍生物複合體
US11952422B2 (en)	2017-12-05	2024-04-09	Chugai Seiyaku Kabushiki Kaisha	Antigen-binding molecule comprising altered antibody variable region binding CD3 and CD137
WO2019135404A1 (en) *	2018-01-05	2019-07-11	Chugai Seiyaku Kabushiki Kaisha	Cytotoxicity-inducing therapeutic agent
JP7570338B2 (ja)	2019-02-15	2024-10-21	インテグラル・モレキュラー・インコーポレイテッド	クローディン６抗体及びその使用
WO2020191342A1 (en)	2019-03-20	2020-09-24	The Regents Of The University Of California	Claudin-6 antibodies and drug conjugates
WO2020196474A1 (ja)	2019-03-25	2020-10-01	第一三共株式会社	抗体－ピロロベンゾジアゼピン誘導体コンジュゲート
AU2020309958A1 (en) *	2019-07-10	2021-12-23	Chugai Seiyaku Kabushiki Kaisha	Claudin-6 binding molecules and uses thereof
CA3159414A1 (en)	2019-12-05	2021-06-10	Seagen Inc.	Anti-av.beta.6 antibodies and antibody-drug conjugates
CR20220540A (es)	2020-03-31	2022-12-07	Chugai Pharmaceutical Co Ltd	Moléculas de union al antígeno multiespecíficas dirigidas a claudina-6 y sus usos
AU2021374036A1 (en)	2020-11-06	2023-06-08	Amgen Inc.	Polypeptide constructs selectively binding to cldn6 and cd3
WO2022183502A1 (zh) *	2021-03-05	2022-09-09	上海吉倍生物技术有限公司	抗cldn6抗体及其用途
US11739144B2 (en)	2021-03-09	2023-08-29	Xencor, Inc.	Heterodimeric antibodies that bind CD3 and CLDN6
JPWO2023053282A1 (pt)	2021-09-29	2023-04-06
JP2025524923A (ja) *	2022-07-29	2025-08-01	レジェンドバイオテックアイルランドリミテッド	クローディン－６結合部分及びその使用
CA3263665A1 (en) *	2022-08-15	2024-02-22	Dana-Farber Cancer Institute, Inc.	Anti-CLDN4 antibodies and their methods of use
CN119947760A (zh)	2022-10-31	2025-05-06	安斯泰来制药株式会社	包含Toll样受体7/8双激动剂化合物的抗体药物复合体
KR20250114330A (ko)	2022-11-30	2025-07-29	인테그럴 몰큘러 인코포레이티드	클라우딘 6을 표적하는 항체 및 이의 이중특이적 형식
WO2024235175A1 (zh) *	2023-05-12	2024-11-21	智泽童康(广州)生物科技有限公司	抗cldn6抗体及其用途
WO2024243561A1 (en)	2023-05-25	2024-11-28	The Regents Of The University Of California	Methods of treating cancer
WO2025162270A1 (zh) *	2024-02-01	2025-08-07	江苏恒瑞医药股份有限公司	抗cldn6抗体、其抗体-药物偶联物及其医药用途
CN118812714B (zh) *	2024-08-21	2025-05-27	广州百吉生物制药有限公司	一种紧密连接蛋白抗体b3及其应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS58201994A (ja)	1982-05-21	1983-11-25	Hideaki Hagiwara	抗原特異的ヒト免疫グロブリンの生産方法
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
DE3920358A1 (de)	1989-06-22	1991-01-17	Behringwerke Ag	Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ATE185601T1 (de)	1990-07-10	1999-10-15	Cambridge Antibody Tech	Verfahren zur herstellung von spezifischen bindungspaargliedern
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
WO1993012227A1 (en)	1991-12-17	1993-06-24	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
JP2938569B2 (ja)	1990-08-29	1999-08-23	ジェンファームインターナショナル，インコーポレイティド	異種免疫グロブリンを作る方法及びトランスジェニックマウス
WO1993006213A1 (en)	1991-09-23	1993-04-01	Medical Research Council	Production of chimeric antibodies - a combinatorial approach
WO1993011161A1 (en)	1991-11-25	1993-06-10	Enzon, Inc.	Multivalent antigen-binding proteins
DE69233782D1 (de)	1991-12-02	2010-05-20	Medical Res Council	Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
JP3507073B2 (ja)	1992-03-24	2004-03-15	ケンブリッジアンティボディーテクノロジーリミティド	特異的結合対の成員の製造方法
EP0652950B1 (en)	1992-07-24	2007-12-19	Amgen Fremont Inc.	Generation of xenogeneic antibodies
US5648267A (en)	1992-11-13	1997-07-15	Idec Pharmaceuticals Corporation	Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
CA2161351C (en)	1993-04-26	2010-12-21	Nils Lonberg	Transgenic non-human animals capable of producing heterologous antibodies
GB9313509D0 (en)	1993-06-30	1993-08-11	Medical Res Council	Chemisynthetic libraries
CA2177367A1 (en)	1993-12-03	1995-06-08	Andrew David Griffiths	Recombinant binding proteins and peptides
KR100261941B1 (ko)	1994-07-13	2000-07-15	나가야마 오사무	사람의 인터루킨-8에 대한 재구성 사람항체
PT1071700E (pt)	1998-04-20	2010-04-23	Glycart Biotechnology Ag	Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
AU773028B2 (en) *	1998-11-03	2004-05-13	Adherex Technologies Inc.	Compounds and methods for modulating claudin-mediated functions
ES2601882T5 (es)	1999-04-09	2021-06-07	Kyowa Kirin Co Ltd	Procedimiento para controlar la actividad de una molécula inmunofuncional
HU231090B1 (hu)	2000-10-06	2020-07-28	Kyowa Kirin Co., Ltd.	Antitest-kompozíciót termelő sejt
JP2005500018A (ja)	2001-04-02	2005-01-06	アイデックファーマスーティカルズコーポレイション	ＧｎＴＩＩＩと同時発現する組換え抗体
HUP0600342A3 (en)	2001-10-25	2011-03-28	Genentech Inc	Glycoprotein compositions
US20040132101A1 (en)	2002-09-27	2004-07-08	Xencor	Optimized Fc variants and methods for their generation
CA2379661A1 (en)	2002-03-28	2003-09-28	Kursad Turksen	Paracellular drug delivery system
AU2003230874A1 (en) *	2002-04-16	2003-11-03	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
WO2003104453A1 (ja)	2002-06-05	2003-12-18	中外製薬株式会社	抗体作製方法
EP1600459A3 (en) *	2002-06-28	2005-12-07	Domantis Limited	Ligand
WO2004004662A2 (en)	2002-07-09	2004-01-15	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
WO2004029207A2 (en) *	2002-09-27	2004-04-08	Xencor Inc.	Optimized fc variants and methods for their generation
JPWO2006067847A1 (ja)	2004-12-22	2008-06-12	中外製薬株式会社	フコーストランスポーターの機能が阻害された細胞を用いた抗体の作製方法
JP2007020155A (ja)	2005-06-08	2007-01-25	Canon Inc	画像処理装置、画像処理方法、プログラム、及び記憶媒体
WO2007041635A2 (en) *	2005-10-03	2007-04-12	Xencor, Inc.	Fc variants with optimized fc receptor binding properties
JP5060068B2 (ja)	2006-06-23	2012-10-31	一般財団法人ファインセラミックスセンター	固体酸化物形燃料電池及びその製造方法

2009
- 2009-01-09 RU RU2010133547/10A patent/RU2010133547A/ru not_active Application Discontinuation
- 2009-01-09 JP JP2009548907A patent/JP5848863B2/ja active Active
- 2009-01-09 KR KR1020107017001A patent/KR20100116179A/ko not_active Withdrawn
- 2009-01-09 EP EP23193707.9A patent/EP4282428A3/en active Pending
- 2009-01-09 CN CN2009801019661A patent/CN101918450A/zh active Pending
- 2009-01-09 WO PCT/JP2009/000082 patent/WO2009087978A1/ja not_active Ceased
- 2009-01-09 US US12/735,359 patent/US9274119B2/en active Active
- 2009-01-09 EP EP16165434.8A patent/EP3064512B1/en active Active
- 2009-01-09 EP EP09700588.8A patent/EP2241578B1/en not_active Revoked
- 2009-01-09 AU AU2009203464A patent/AU2009203464A1/en not_active Abandoned
- 2009-01-09 MX MX2010007500A patent/MX2010007500A/es active IP Right Grant
- 2009-01-09 BR BRPI0907237-3A patent/BRPI0907237A2/pt not_active IP Right Cessation
- 2009-01-09 CA CA2711557A patent/CA2711557A1/en not_active Abandoned
- 2009-01-09 SG SG2013002365A patent/SG187457A1/en unknown

Also Published As

Publication number	Publication date
EP2241578A4 (en)	2012-09-12
EP4282428A2 (en)	2023-11-29
US9274119B2 (en)	2016-03-01
EP3064512B1 (en)	2023-08-30
WO2009087978A1 (ja)	2009-07-16
US20110059469A1 (en)	2011-03-10
JPWO2009087978A1 (ja)	2011-05-26
CN101918450A (zh)	2010-12-15
AU2009203464A1 (en)	2009-07-16
SG187457A1 (en)	2013-02-28
EP2241578B1 (en)	2016-04-20
EP3064512A3 (en)	2016-10-19
EP2241578A1 (en)	2010-10-20
MX2010007500A (es)	2010-10-20
CA2711557A1 (en)	2009-07-16
RU2010133547A (ru)	2012-02-20
EP3064512C0 (en)	2023-08-30
EP3064512A2 (en)	2016-09-07
EP4282428A3 (en)	2024-03-20
JP5848863B2 (ja)	2016-01-27
KR20100116179A (ko)	2010-10-29

Publication	Publication Date	Title
CY2019004I1 (el)	2019-11-27	Τροποποιημενα αντισωματα αντι-ιl-23ρ19
BRPI0907237A2 (pt)	2015-07-14	Anticorpo anti-cldn6
HRP20171011T1 (hr)	2017-09-22	ANTI-eMET ANTITIJELO
IL212175B (en)	2019-08-29	Muc1* antibodies
BRPI0906877A2 (pt)	2015-07-28	Anticorpos anti-trkb aperfeiçoados
EP2337798A4 (en)	2012-10-24	SPECIFIC ANTIBODIES OF THE ASB
DK3072906T3 (da)	2021-12-13	Antistofformulering
EP2358392A4 (en)	2012-08-29	ANTIBODY FORMULATION
PT2406284T (pt)	2016-09-29	Anticorpos anti-bcma
PT2813570T (pt)	2018-02-12	Resumo
DE602009000234D1 (de)	2010-11-11	msignals
BRPI0907376A2 (pt)	2015-07-14	Fotobiorretador
PT3045471T (pt)	2017-06-14	Resumo
BRPI0914649A2 (pt)	2015-07-07	Piprazolo-quinazolinas
DE602008003972D1 (de)	2011-01-27	Sitzrücklehnungsmechanismus
DE602008003521D1 (de)	2010-12-30	Sitzrücklehnungsmechanismus
BRPI0909633A2 (pt)	2015-09-22	anticorpos anti-tyrp1
BRPI0817427A2 (pt)	2015-06-16	Anticorpo anti-bst2
DK2271613T3 (da)	2014-07-14	Hydroxymethylcyklohexylaminer
DE602008003970D1 (de)	2011-01-27	Strahlstromkalibriersystem
BRPI0907522A2 (pt)	2019-09-24	biarlamidas
DE112009000183A5 (de)	2011-02-03	Sicherheitsvorreiber
BRPI0909634A2 (pt)	2015-09-22	2-aminoquinolinas
DE602009000862D1 (de)	2011-04-28	Gehwagenbremse
BRPI0912769A2 (pt)	2015-10-13	anticorpos anti-pirb

Legal Events

Date	Code	Title	Description
2015-08-25	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 6A ANUIDADE.
2016-05-10	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2329 DE 25-08-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.